Psyched Wellness Sees Professor David Nutt Move From Advisory Role To Directorship
It appears that Professor David Nutt has a desire to become more involved with that of Psyched Wellness (CSE: PSYC). Currently the chair of the Scientific Advisory Board for Compass Pathways (NASDAQ: CMPS), Nutt has elected to step up from his role as an advisor to Psyched Wellness to that of a directorship.
Nutt is well versed in the area of psychopharmacology, which is the study of the effects of drugs on the brain. In layman terms, his focus is on how and why addictions can occur, as well as how treatments in both psychiatry and neurology work. Presently, he works as a psychiatrist as the Edmond J. Safra Chair of Neuropsychopharmacology at Imperial College London, within the Division of Brain Sciences.
Speaking specifically to his work, Nutt is well respected within the field, with his research having lead to over 500 original research papers. Furthermore, a comparable number of reviews and book chapters have been written by Nutt, along with eight government reports on drugs and 35 books. Not all of his writing has been directed to the medical community specifically, with one book, Drugs: Without the Hot Air, being written for consumption by the general public.
Past roles held by Nutt are rather impressive as well, with him having served as President of four separate medical councils: The European Brain Council, the European College of Neuropsychopharmacology, the British Association of Pharmacology, and the British Neuroscience Association. He’s also the founding chair of Drug Science, while holding visiting professorships at multiple universities.
“As a recent pioneer in the field of psychedelic medicine I have long been fascinated by the centuries-old use of Amanita Muscaria. When Psyched Wellness offered me the chance to bring this novel psychedelic mushroom into modern science and medicine, I jumped at it!”
Professor David Nutt
Psyched Wellness last traded at $0.13 on the CSE.
FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
